Global Blood Plasma Derivatives Market Size By Type (Albumin, Factor VIII), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Blood Plasma Derivatives Market was valued at USD 31.6 billion in 2023 and is expected to surpass USD 57.4 billion by 2031, expanding at a compound annual growth rate (CAGR) of 8.1% from 2023 to 2031. This growth is driven by rising incidences of chronic diseases such as immunodeficiencies, hemophilia, and neurological conditions, coupled with the increasing use of plasma derivatives in surgical procedures and emergency care. Furthermore, technological advancements in plasma fractionation techniques and a strong pipeline of plasma-derived therapies continue to boost market expansion.

Drivers:

Rising Prevalence of Chronic Diseases:

The increasing incidence of immunodeficiency disorders, autoimmune diseases, and bleeding disorders is significantly driving demand for immunoglobulins, albumin, and coagulation factors.

Advancements in Plasma Processing Technologies:

Innovations in fractionation processes, purification techniques, and pathogen reduction technologies are improving yield and safety, making plasma derivatives more accessible and efficient.

Growth in Surgical Procedures and Trauma Care:

Blood plasma derivatives are critical in managing bleeding and supporting recovery, fueling their demand across emergency rooms, surgical centers, and trauma care units.

Restraints:

Limited Plasma Supply:

Despite growing demand, plasma collection remains a time-consuming and regulated process, leading to potential shortages that can constrain market growth.

High Production Costs and Complex Regulation:

The complex manufacturing and quality control processes required for plasma derivatives lead to high operational costs. Additionally, regulatory scrutiny adds to time and cost burdens for product approvals.

Opportunity:

Expansion in Emerging Markets:

Emerging economies like India, Brazil, and Southeast Asia are investing heavily in healthcare infrastructure. The rising awareness and increasing patient pool create untapped opportunities for plasma derivative products.

R&D for New Indications:

Ongoing research into the therapeutic applications of plasma derivatives for neurological, infectious, and metabolic diseases presents new growth avenues for market players.

Market by System Type Insights:

Based on product type, the Immunoglobulin segment dominated the market in 2023, accounting for the largest share due to its widespread application in treating immunodeficiency and autoimmune disorders. The Coagulation Factor segment is projected to witness the fastest growth during the forecast period, particularly driven by its expanding use in hemophilia management.

Market by End-use Insights:

Hospitals held the largest revenue share in 2023 owing to the growing number of surgical interventions and chronic disease treatments requiring plasma derivatives. Blood collection centers and diagnostic laboratories also represent significant end-users, contributing to the segment’s growth through large-scale collection, processing, and testing efforts.

Market by Regional Insights:

North America led the market in 2023, supported by high healthcare expenditure, advanced infrastructure, and strong regulatory compliance. Europe follows closely due to robust donation networks and patient awareness. However, Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, driven by population growth, improving healthcare access, and policy support for local plasma collection.

Competitive Scenario:

Major players in the global blood plasma derivatives market include:

CSL Behring

Grifols, S.A.

Takeda Pharmaceutical Company Limited

Kedrion S.p.A.

Octapharma AG

Bio Products Laboratory Ltd.

China Biologic Products Holdings, Inc.

Sanquin

ADMA Biologics

Green Cross Corporation

These companies are actively investing in strategic expansions, acquisitions, and development of novel therapies. For instance:

In 2023, CSL Behring launched a next-generation subcutaneous immunoglobulin product in Europe.

Takeda expanded its plasma collection centers in North America in 2024 to address increasing global demand.

Grifols introduced an AI-based donor management system in 2023 to enhance plasma collection efficiency.

Scope of Work – Global Blood Plasma Derivatives Market

Report Metric Details

Market Size (2023) USD 31.6 billion

Projected Market Size (2031) USD 57.4 billion

CAGR (2023–2031) 8.1%

Market Segments By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Others), By End-Use (Hospitals, Diagnostic Laboratories, Blood Collection Cent